Aldeyra Therapeutics Inc (STU:137)
€ 4.609 -0.037 (-0.79%) Market Cap: 276.29 Mil Enterprise Value: 184.32 Mil PE Ratio: 0 PB Ratio: 3.43 GF Score: 39/100

Aldeyra Therapeutics Inc at Citi BioPharma Conference (Virtual) Transcript

Sep 09, 2021 / 12:50PM GMT
Release Date Price: €7.5
Yigal Dov Nochomovitz
Citigroup Inc., Research Division - Director

Great. Welcome, everyone. I'm Yigal Nochomovitz. I'm one of the biotech analysts here at Citi. This is our panel on next-generation retinal therapeutics. It's my great pleasure to have with me today from Aerie Pharma, Vince Anido, who's the Chairman and CEO; from Aldeyra Therapeutics, Todd Brady, the CEO; and from Opthea Limited in Australia, Megan Baldwin, the CEO.

So welcome, everyone. Thank you so much for taking the time to participate in our panel. I think as a starting point, since some of the listeners may be less familiar with your companies, why don't we just do a 2- to 3-minute intro for each of you as to what you're focused on, what the pipeline is at your company and maybe 1 or 2 of the key upcoming data points.

So maybe, Todd, do you want to kick it off?

Todd C. Brady
Aldeyra Therapeutics, Inc. - CEO, President & Director

Thanks, Yigal, and thanks for having us on the conference today. Aldeyra is an immunology company at heart. We've started out in the eye,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot